Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Adriamycin RDF (doxorubicin)
- porfimer
Interactions between your drugs
DOXOrubicin porfimer
Applies to: Adriamycin RDF (doxorubicin), porfimer
Using porfimer together with DOXOrubicin may increase the risk of a photosensitivity reaction (e.G., redness, swelling, itching, burning sensation, feeling hot, and/or blisters), following exposure to sunlight or bright indoor lights such as examination, dental or operating room lamps; floodlights; halogen lights; and unshaded light bulbs at close proximity. It is recommended that DOXOrubicin be avoided for at least 30 days following therapy with porfimer, and until a test for residual photosensitivity shows no photosensitivity reaction within 24 hours. In some cases, it might be necessary to avoid photosensitizing medications for 90 days or longer, although it may not be feasible to interrupt some treatments for that long, especially if they are medically necessary. Exposing your skin to normal indoor lighting is helpful as it will help your body get rid of porfimer more quickly, so you do not need to stay inside in the dark. Check with your doctor to see if you should temporarily withhold any of your medications after taking porfimer or if you have any other questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.